Patient satisfaction at 24 months after treatment for localized prostate cancer
The ability to “manage” patients’ satisfaction with their care in the treatment of localized prostate cancer is challenging — for patients, for caregivers, for physicians, and for health systems. While...
View ArticleThe first-line treatment of locally advanced prostate cancer (clinical stage T3)
Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy...
View ArticleProstate cancer treatment and quality of life in the “real world”
The idea that most men will recover meaningful erectile and sexual function after treatment for prostate cancer has long been disputed by many in the patient community. We now seem to have some better...
View ArticleSynergy between radiation of metastases and immunotherapy confirmed
Two clinical trials have now confirmed the abscopal or bystander effect in prostate cancer. These effects occur when cancer cells that are not directly treated are nonetheless killed. All cancer...
View ArticleThe virtual prostate cancer patient
A new type of “educational” service has been brought to our attention that uses virtual reality (VR) systems allowing a number of opportunities for men to “talk” to a virtual prostate cancer patient...
View ArticleOnvansertib in treatment of abiraterone-resistant mCRPC
We hear that an investigational drug called onvansertib — a so-called polo-like kinase 1 (PLK1) inhibitor — may have benefit in the treatment of men with metastatic, castration-resistant prostate...
View Article